^
    2d
    Complete remission of relapsed ATXN2L::JAK2 fusion positive anaplastic large cell lymphoma following ruxolitinib monotherapy in a child. (PubMed, NPJ Precis Oncol)
    Consolidative allogeneic hematopoietic stem cell transplant HSCT then lead to long-term remission. This case underscores the critical role of comprehensive genomic profiling for rare histologies and supports the potential utility of JAK/STAT pathway inhibitors in select patients with ALK-negative ALCL.
    Journal
    |
    ALK (Anaplastic lymphoma kinase) • JAK2 (Janus kinase 2)
    |
    ALK negative
    |
    Jakafi (ruxolitinib)
    3d
    SENTRY-2: A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia (clinicaltrials.gov)
    P2, N=58, Recruiting, Karyopharm Therapeutics Inc | N=118 --> 58 | Trial primary completion date: Apr 2026 --> Jun 2027
    Enrollment change • Trial primary completion date
    |
    Jakafi (ruxolitinib) • Xpovio (selinexor) • Vonjo (pacritinib) • Ojjaara (momelotinib)
    5d
    Life-Threatening Thrombotic Events Revealing Systemic Lupus Erythematosus in a Patient with Chronic Myelomonocytic Leukaemia. (PubMed, Eur J Case Rep Intern Med)
    There is a two-way relationship between hematologic malignancies and autoimmune diseases, where each can potentially initiate or exacerbate the other.Effective management requires close collaboration between haematologists, immunologists/rheumatologists, and intensive care specialists.
    Journal
    |
    NRAS (Neuroblastoma RAS viral oncogene homolog)
    |
    NRAS mutation
    |
    Venclexta (venetoclax) • azacitidine • Jakafi (ruxolitinib) • hydroxychloroquine • hydroxyurea
    5d
    NCI-2022-02385: Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia (clinicaltrials.gov)
    P2, N=30, Recruiting, Jonathan Brammer | Trial completion date: Dec 2025 --> Jul 2026 | Trial primary completion date: Dec 2025 --> Jul 2026
    Trial completion date • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • B3GAT1 (Beta-1,3-Glucuronyltransferase 1)
    |
    Jakafi (ruxolitinib)
    6d
    Open Label Phase 1/2 Study of Tasquinimod in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), or Post-Essential Thrombocytosis Myelofibrosis (Post-ET MF) (clinicaltrials.gov)
    P1/2, N=1, Active, not recruiting, M.D. Anderson Cancer Center | Phase classification: P2 --> P1/2
    Phase classification
    |
    Jakafi (ruxolitinib) • tasquinimod (ABR-215050)
    12d
    Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer (clinicaltrials.gov)
    P2, N=23, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Dec 2025 --> Apr 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    paclitaxel • doxorubicin hydrochloride • Jakafi (ruxolitinib) • cyclophosphamide
    15d
    Phase I Trial for Patients w/ Advanced Hematologic Malignancies Undergoing Allogeneic HCT (clinicaltrials.gov)
    P1, N=24, Recruiting, Stanford University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-C (Major Histocompatibility Complex, Class I, C)
    |
    Jakafi (ruxolitinib) • Orca-T
    15d
    NCI-2020-01626: Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis (clinicaltrials.gov)
    P2, N=79, Active, not recruiting, Fred Hutchinson Cancer Center | Recruiting --> Active, not recruiting | N=60 --> 79 | Trial completion date: Dec 2029 --> Apr 2030
    Enrollment closed • Enrollment change • Trial completion date
    |
    Jakafi (ruxolitinib) • cyclophosphamide • methotrexate • melphalan • fludarabine IV • busulfan
    16d
    A clinical study of ruxolitinib combined with reduced-dose HLH-1994 regimen in the treatment of adult hemophagocytic lymphohistiocytosis (ChiCTR2500115370)
    P=N/A, N=20, Not yet recruiting, Shandong Provincial Qianfoshan Hospital; Shandong Provincial Qianfoshan Hospital
    New trial
    |
    Jakafi (ruxolitinib)
    16d
    A randomized, double-blind, excipi-controlled, multicenter Phase III clinical study to evaluate the efficacy and safety of ruxolitinib gel (HDM3010) in adult subjects with mild to moderate pruritus nodules (ChiCTR2600117276)
    P3, N=360, Not yet recruiting, Hangzhou First People's Hospital; Hangzhou First People's Hospital
    New P3 trial
    |
    Jakafi (ruxolitinib)
    16d
    Efficacy and Safety of Ruxolitinib Combined with Decitabine in Treating High-Risk Myelofibrosis Patients: A Prospective, Multicenter, Phase II Clinical Study Protocol (ChiCTR2600117487)
    P2, N=36, Not yet recruiting, The First Affiliated Hospital of Zhejiang University School of Medicine; The First Affiliated Hospital of Zhejiang University School of Medicine
    New P2 trial
    |
    Jakafi (ruxolitinib) • decitabine
    17d
    Interferon-Type-I Response and Autophagy Independently Regulate Radiation-Induced HLA-Class-I Molecule Expression in Lung Cancer. (PubMed, Curr Issues Mol Biol)
    The effect of RT (8 and 3 × 8 Gy) on Interferon beta (IFNβ), IFN-stimulated genes (ISGs), and HLA-class-I expression in combination with IFN-type-I-response inhibitors (Ruxolitinib, Tofacitinib, Amlexanox) targeting the JAK and TBK1 was studied with Flow cytometry and RT-PCR. The current study supports the theory that baseline autophagy, RT-induced autophagy blockage, and IFN-type-I response enhancement define the HLA-class-I levels in NSCLC cells. This complex interplay emerges as a promising target for the development of radio-vaccination strategies to enhance the efficacy of radio-immunotherapy.
    Journal • IO biomarker
    |
    ATG7 (Autophagy Related 7) • IFNB1 (Interferon Beta 1) • MAP1LC3A (Microtubule Associated Protein 1 Light Chain 3 Alpha)
    |
    Jakafi (ruxolitinib) • Aphthasol (amlexanox) • tofacitinib